Will Wave Life Sciences maintain cash and equivalents above $400M at Q3 2026 quarter-end?
Current Prediction
Why This Question Matters
Cash runway is the binding constraint identified by the Stress Scanner. Quarterly cash balance below $400M without announced financing would signal compressed runway. This market tests whether the burn rate remains manageable or accelerates beyond guidance.
Prediction Distribution
Individual Predictions(9 runs)
Central estimate ~$430-450M at Q3 2026, but sensitive to burn rate acceleration. Starting at $602M with Q3 2028 guided runway provides partial support, but r&d at $52.8m and rising creates counterweight. Probability: 0.6.
Central estimate ~$430-450M at Q3 2026, but sensitive to burn rate acceleration. Starting at $602M with Q3 2028 guided runway provides partial support, but r&d at $52.8m and rising creates counterweight. Probability: 0.51.
Central estimate ~$430-450M at Q3 2026, but sensitive to burn rate acceleration. Starting at $602M with Q3 2028 guided runway provides partial support, but r&d at $52.8m and rising creates counterweight. Probability: 0.56.
Base rate evidence: r&d at $52.8m and rising. Partial offset from starting at $602m with q3 2028 guided runway. Central estimate ~$430-450M at Q3 2026, but sensitive to burn rate acceleration. Probability: 0.56.
Base rate evidence: r&d at $52.8m and rising. Partial offset from starting at $602m with q3 2028 guided runway. Central estimate ~$430-450M at Q3 2026, but sensitive to burn rate acceleration. Probability: 0.61.
Base rate evidence: r&d at $52.8m and rising. Partial offset from starting at $602m with q3 2028 guided runway. Central estimate ~$430-450M at Q3 2026, but sensitive to burn rate acceleration. Probability: 0.66.
Central estimate ~$430-450M at Q3 2026, but sensitive to burn rate acceleration. Balance of evidence suggests 0.58 probability. Primary support: starting at $602m with q3 2028 guided runway. Main counterargument: r&d at $52.8m and rising.
Central estimate ~$430-450M at Q3 2026, but sensitive to burn rate acceleration. Balance of evidence suggests 0.6 probability. Primary support: starting at $602m with q3 2028 guided runway. Main counterargument: r&d at $52.8m and rising.
Central estimate ~$430-450M at Q3 2026, but sensitive to burn rate acceleration. Balance of evidence suggests 0.59 probability. Primary support: starting at $602m with q3 2028 guided runway. Main counterargument: r&d at $52.8m and rising.
Resolution Criteria
Resolves YES if Wave reports cash, cash equivalents, and short-term investments above $400M at Q3 2026 quarter-end. Resolves NO if below $400M.
Resolution Source
Wave Life Sciences Q3 2026 10-Q filing
Source Trigger
Cash balance at $602M (Q4 2025); below $400M without financing would signal compressed runway. R&D burn at $52.8M/quarter and accelerating
Full multi-lens equity analysis